Investor Gilde Healthcare Holding B.V.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Gilde Healthcare Holding B.V. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-05 13D SI / Shoulder Innovations, Inc. 2,380,482
2022-10-13 13D/A EAR / Eargo, Inc. 2,119,290 1,869,290
2022-10-11 13D/A EAR / Eargo, Inc. 2,760,912 2,119,290
2022-10-06 13D/A EAR / Eargo, Inc. 3,311,894 2,760,912
2022-04-21 13G AFMD / Affimed N.V. 8,125,000
2022-02-10 13G NYXH / Nyxoah SA 3,153,822
2021-04-28 13D/A EAR / Eargo, Inc. 3,919,802 3,311,894
2020-10-30 13D EAR / Eargo, Inc. 3,919,802
2020-05-19 13D/A VAPO / Vapotherm, Inc. 1,189,026 1,189,026
2019-11-07 13D/A VAPO / Vapotherm, Inc. 1,189,026 1,189,026
2019-01-11 13D VAPO / Vapotherm, Inc. 1,189,026
2017-02-07 13G/A ASND / Ascendis Pharma A/S - Depositary Receipt (Common Stock) 1,859,136 0
2017-02-07 13G/A QURE / uniQure N.V. 1,282,789 1,056,946
2016-02-09 13G ASND / Ascendis Pharma A/S - Depositary Receipt (Common Stock) 1,859,136
2016-02-09 13G/A QURE / uniQure N.V. 1,282,789
2015-01-21 13G/A CNAT / Conatus Pharmaceuticals Inc. 554,298
2015-01-21 13G QURE / uniQure N.V. 1,730,415
2014-02-11 13G CNAT / Conatus Pharmaceuticals Inc. 1,514,298